報價延遲最少15分鐘:2025/07/02 20:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
27.58 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.42/1.21
|
|
企業價值
2.18B
|
| 資產負債 |
|
每股賬面淨值
15.26
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
445.76M
|
|
每股收益
4.38
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/02 20:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies. |